This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.82% per year. These returns cover a period from January 1, 1988 through October 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
BMY Up 3% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?
by Ekta Bagri
Bristol Myers Squibb gains 3% after beating third-quarter estimates, as its Growth Portfolio and promising pipeline support revenue prospects despite generic competition.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up
by Zacks Equity Research
Regeneron's Q3 earnings and revenues beat estimates, fueled by strong Dupixent profits, Eylea HD growth and robust Libtayo demand. Stock up.
REGNPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
ABBV Beats on Q3 Earnings & Sales, Stock Rises on Raised '26 EPS View
by Zacks Equity Research
AbbVie beats Q3 earnings and revenue estimates as strong immunology and neuroscience sales drive growth, prompting a higher 2026 EPS outlook.
ABBVNegative Net Change RHHBYNegative Net Change JNJNegative Net Change
biotechs earnings medical pharmaceuticals
VKTX: Is a 2029 Launch for Its Obesity Drug Within Reach?
by Sundeep Ganoria
Viking Therapeutics is set to target a potential first-half 2029 launch for VK2735, but clinical readouts, FDA review and intensifying competition could shape its timeline.
VKTXNegative Net Change NVONegative Net Change LLYNegative Net Change
biotechs medical pharmaceuticals
GILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales Growth
by Zacks Equity Research
Gilead tops Q3 earnings and revenue estimates as HIV sales, Trodelvy and Livdelzi drive growth, prompting an increase in 2026 product sales guidance.
GILDNegative Net Change TGTXPositive Net Change IOVAPositive Net Change AMRXNegative Net Change
biotechnology biotechs medical pharmaceuticals
ALNY Stock Down 25% Despite Q3 Earnings Beat on Demand Growth Concerns
by Zacks Equity Research
Alnylam's shares fall 25% despite Q3 beat as slower Amvuttra patient starts and demand concerns weigh on investor sentiment.
ALNYPositive Net Change REGNPositive Net Change NVSNegative Net Change RHHBYNegative Net Change
biotechnology biotechs medical pharmaceuticals
3 Promising Genomics Stocks to Add to Your Portfolio Now
by Ekta Bagri
Genomics and synthetic biology are transforming healthcare through precision medicine and gene editing, putting ILMN, QURE and TXG in focus as the markets expand.
ILMNPositive Net Change QUREPositive Net Change TXGPositive Net Change BEAMPositive Net Change CRSPNo Net Change
biotechnology biotechs genetics genomics medical pharmaceuticals
HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Halozyme is poised for a Q3 earnings beat as strong demand for partnered drugs is likely to boost royalties and drive the top line.
HALONegative Net Change JNJNegative Net Change PFENegative Net Change AMRXNegative Net Change
biotechs
VKTX Q3 Earnings Miss Estimates Amid Rising Clinical Expenses
by Zacks Equity Research
Viking Therapeutics' Q3 loss widens as rising costs weigh on results, while its obesity drug candidate advances through phase III studies.
VKTXNegative Net Change TGTXPositive Net Change AMRXNegative Net Change
biotechs earnings medical
GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?
by Sundeep Ganoria
GSK's Specialty Medicines growth, deep pipeline and dividend offer a compelling case against MRNA's oncology potential and premium valuation.
GSKNegative Net Change MRNAPositive Net Change PFENegative Net Change MRKNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines